IQV vs. VEEV: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at IQV and VEEV, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | IQV | VEEV |
|---|---|---|
| Company Name | IQVIA Holdings Inc. | Veeva Systems Inc. |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Life Sciences Tools & Services | Health Care Technology |
| Market Capitalization | 32.10 billion USD | 47.98 billion USD |
| Exchange | NYSE | NYSE |
| Listing Date | May 9, 2013 | October 16, 2013 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of IQV and VEEV by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | IQV | VEEV |
|---|---|---|
| 5-Day Price Return | 1.84% | 4.01% |
| 13-Week Price Return | 34.34% | 23.33% |
| 26-Week Price Return | -1.17% | 30.03% |
| 52-Week Price Return | -23.83% | 47.66% |
| Month-to-Date Return | 1.58% | 3.30% |
| Year-to-Date Return | -3.92% | 39.64% |
| 10-Day Avg. Volume | 1.16M | 1.20M |
| 3-Month Avg. Volume | 2.16M | 1.36M |
| 3-Month Volatility | 45.26% | 42.71% |
| Beta | 1.34 | 0.97 |
Profitability
Return on Equity (TTM)
IQV
19.96%
Life Sciences Tools & Services Industry
- Max
- 19.96%
- Q3
- 11.55%
- Median
- 6.22%
- Q1
- 3.86%
- Min
- -6.95%
In the upper quartile for the Life Sciences Tools & Services industry, IQV’s Return on Equity of 19.96% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
VEEV
13.74%
Health Care Technology Industry
- Max
- 47.95%
- Q3
- 35.17%
- Median
- 13.74%
- Q1
- 11.05%
- Min
- 11.05%
VEEV’s Return on Equity of 13.74% is on par with the norm for the Health Care Technology industry, indicating its profitability relative to shareholder equity is typical for the sector.
Net Profit Margin (TTM)
IQV
7.88%
Life Sciences Tools & Services Industry
- Max
- 27.28%
- Q3
- 16.17%
- Median
- 7.24%
- Q1
- 3.00%
- Min
- -3.05%
IQV’s Net Profit Margin of 7.88% is aligned with the median group of its peers in the Life Sciences Tools & Services industry. This indicates its ability to convert revenue into profit is typical for the sector.
VEEV
27.34%
Health Care Technology Industry
- Max
- 51.50%
- Q3
- 45.32%
- Median
- 27.34%
- Q1
- 14.21%
- Min
- 14.21%
VEEV’s Net Profit Margin of 27.34% is aligned with the median group of its peers in the Health Care Technology industry. This indicates its ability to convert revenue into profit is typical for the sector.
Operating Profit Margin (TTM)
IQV
13.85%
Life Sciences Tools & Services Industry
- Max
- 33.15%
- Q3
- 19.34%
- Median
- 13.02%
- Q1
- 8.05%
- Min
- -4.38%
IQV’s Operating Profit Margin of 13.85% is around the midpoint for the Life Sciences Tools & Services industry, indicating that its efficiency in managing core business operations is typical for the sector.
VEEV
26.97%
Health Care Technology Industry
- Max
- 73.15%
- Q3
- 56.55%
- Median
- 26.97%
- Q1
- 22.10%
- Min
- 22.10%
VEEV’s Operating Profit Margin of 26.97% is around the midpoint for the Health Care Technology industry, indicating that its efficiency in managing core business operations is typical for the sector.
Profitability at a Glance
| Symbol | IQV | VEEV |
|---|---|---|
| Return on Equity (TTM) | 19.96% | 13.74% |
| Return on Assets (TTM) | 4.50% | 11.20% |
| Net Profit Margin (TTM) | 7.88% | 27.34% |
| Operating Profit Margin (TTM) | 13.85% | 26.97% |
| Gross Profit Margin (TTM) | 34.25% | 75.50% |
Financial Strength
Current Ratio (MRQ)
IQV
0.84
Life Sciences Tools & Services Industry
- Max
- 4.76
- Q3
- 2.77
- Median
- 1.85
- Q1
- 1.40
- Min
- 0.43
IQV’s Current Ratio of 0.84 falls into the lower quartile for the Life Sciences Tools & Services industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
VEEV
4.60
Health Care Technology Industry
- Max
- 7.04
- Q3
- 7.01
- Median
- 4.60
- Q1
- 2.96
- Min
- 0.31
VEEV’s Current Ratio of 4.60 aligns with the median group of the Health Care Technology industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
IQV
2.68
Life Sciences Tools & Services Industry
- Max
- 1.75
- Q3
- 0.83
- Median
- 0.41
- Q1
- 0.18
- Min
- 0.00
With a Debt-to-Equity Ratio of 2.68, IQV operates with exceptionally high leverage compared to the Life Sciences Tools & Services industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.
VEEV
0.00
Health Care Technology Industry
- Max
- 0.06
- Q3
- 0.05
- Median
- 0.01
- Q1
- 0.00
- Min
- 0.00
Falling into the lower quartile for the Health Care Technology industry, VEEV’s Debt-to-Equity Ratio of 0.00 points to a conservative financing strategy. This results in lower financial risk but potentially limits strategic investments compared to more leveraged competitors.
Interest Coverage Ratio (TTM)
IQV
3.68
Life Sciences Tools & Services Industry
- Max
- 29.61
- Q3
- 23.24
- Median
- 6.07
- Q1
- 2.18
- Min
- -14.08
IQV’s Interest Coverage Ratio of 3.68 is positioned comfortably within the norm for the Life Sciences Tools & Services industry, indicating a standard and healthy capacity to cover its interest payments.
VEEV
169.00
Health Care Technology Industry
- Max
- 224.12
- Q3
- 222.84
- Median
- 219.00
- Q1
- 181.50
- Min
- 169.00
In the lower quartile for the Health Care Technology industry, VEEV’s Interest Coverage Ratio of 169.00 indicates a tighter cushion for servicing debt, suggesting less financial flexibility than many of its competitors.
Financial Strength at a Glance
| Symbol | IQV | VEEV |
|---|---|---|
| Current Ratio (MRQ) | 0.84 | 4.60 |
| Quick Ratio (MRQ) | 0.81 | 4.54 |
| Debt-to-Equity Ratio (MRQ) | 2.68 | 0.00 |
| Interest Coverage Ratio (TTM) | 3.68 | 169.00 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
IQV
0.00%
Life Sciences Tools & Services Industry
- Max
- 1.80%
- Q3
- 0.78%
- Median
- 0.37%
- Q1
- 0.00%
- Min
- 0.00%
IQV currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
VEEV
0.00%
Health Care Technology Industry
- Max
- 1.12%
- Q3
- 0.62%
- Median
- 0.12%
- Q1
- 0.00%
- Min
- 0.00%
VEEV currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
IQV
0.00%
Life Sciences Tools & Services Industry
- Max
- 156.00%
- Q3
- 65.73%
- Median
- 23.81%
- Q1
- 0.00%
- Min
- 0.00%
IQV has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
VEEV
0.00%
Health Care Technology Industry
- Max
- 101.92%
- Q3
- 72.22%
- Median
- 42.51%
- Q1
- 0.00%
- Min
- 0.00%
VEEV has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | IQV | VEEV |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
IQV
26.37
Life Sciences Tools & Services Industry
- Max
- 117.96
- Q3
- 65.59
- Median
- 37.26
- Q1
- 27.51
- Min
- 1.73
In the lower quartile for the Life Sciences Tools & Services industry, IQV’s P/E Ratio of 26.37 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
VEEV
59.28
Health Care Technology Industry
- Max
- 343.51
- Q3
- 272.61
- Median
- 54.67
- Q1
- 36.04
- Min
- 31.57
VEEV’s P/E Ratio of 59.28 is within the middle range for the Health Care Technology industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Price-to-Sales Ratio (TTM)
IQV
2.08
Life Sciences Tools & Services Industry
- Max
- 12.46
- Q3
- 6.70
- Median
- 4.24
- Q1
- 2.68
- Min
- 0.73
In the lower quartile for the Life Sciences Tools & Services industry, IQV’s P/S Ratio of 2.08 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
VEEV
16.21
Health Care Technology Industry
- Max
- 176.90
- Q3
- 98.12
- Median
- 16.38
- Q1
- 4.49
- Min
- 0.00
VEEV’s P/S Ratio of 16.21 aligns with the market consensus for the Health Care Technology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio (MRQ)
IQV
4.72
Life Sciences Tools & Services Industry
- Max
- 7.99
- Q3
- 4.69
- Median
- 3.30
- Q1
- 1.88
- Min
- 1.02
IQV’s P/B Ratio of 4.72 is in the upper tier for the Life Sciences Tools & Services industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.
VEEV
6.13
Health Care Technology Industry
- Max
- 117.60
- Q3
- 90.72
- Median
- 8.09
- Q1
- 3.83
- Min
- 3.06
VEEV’s P/B Ratio of 6.13 is within the conventional range for the Health Care Technology industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
Valuation at a Glance
| Symbol | IQV | VEEV |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 26.37 | 59.28 |
| Price-to-Sales Ratio (TTM) | 2.08 | 16.21 |
| Price-to-Book Ratio (MRQ) | 4.72 | 6.13 |
| Price-to-Free Cash Flow Ratio (TTM) | 16.23 | 39.03 |